Answers are grounded in this paper and cite their sources.
HCQ restores antiestrogen sensitivity to resistant tumors. Moreover, the beneficial combination of TAM+HCQ suggests a positive outcome for ongoing neoadjuvant clinical trials using this combination for the treatment of ER(+) ductal carcinoma in situ lesions.
No takes yet. Share an insight, caveat, or question.
Cook et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: